Volume 11 Supplement 2

Proceedings of 20th Pediatric Rheumatology European Society (PReS) Congress

Open Access

PReS-FINAL-2100: Methotrexate treatment affects effector, but not regulatory T cells in juvenile idiopathic arthritis

  • S Vastert1,
  • M Bulatovic-Calasan2,
  • R Scholman3,
  • M Klein3,
  • N Wulffraat3,
  • B Prakken3 and
  • FV Wijk3
Pediatric Rheumatology201311(Suppl 2):P112

https://doi.org/10.1186/1546-0096-11-S2-P112

Published: 5 December 2013

Introduction

The balance between regulatory (Treg) and effector T cells (Teff) is crucial for immune regulation in juvenile idiopathic arthritis (JIA). How methotrexate (MTX), the cornerstone treatment in JIA, influences this balance in vivo is poorly elucidated.

Objectives

To investigate quantitative and qualitative effects of MTX on Treg and Teff in JIA patients during MTX treatment.

Methods

Peripheral blood samples were obtained from JIA patients at MTX start and 3 and 6 months thereafter. Treg numbers and phenotype were determined by flow cytometry and suppressive function in allogeneic suppression assays. Teff proliferation upon stimulation with anti-CD3, activation status and intracellular cytokine production were determined by flow cytometry. Effector cell responsiveness to suppression was investigated in autologous suppression assays. Effector cell cytokines in supernatants of proliferation and suppression assays and in plasma were measured by cytokine multiplex assay.

Results

MTX treatment in JIA did not affect Treg phenotype and function. Instead, MTX treatment enhanced, rather than diminished, CD4+ and CD8+ T cell proliferation of JIA patients after 6 months of therapy, independent of clinical response. Effector cells during MTX treatment were equally responsive to Treg-mediated suppression. MTX treatment did not attenuate Teff activation status and their capacity to produce IL-13, IL-17, tnfα and ifnγ. Similarly to Teff proliferation, plasma ifnγ concentrations after 6 months were increased.

Conclusion

This study provides a novel insight that MTX treatment in JIA does not attenuate Teff function but conversely, enhances T cell proliferation and ifnγ plasma concentrations in JIA patients.

Disclosure of interest

S. Vastert Consultant for: Novartis, < 1000 euro's., M. Bulatovic-Calasan: None declared., R. Scholman: None declared., M. Klein: None declared., N. Wulffraat Grant/Research Support from: Abbvie, Roche, Consultant for: Novartis, Pfizer, B. Prakken: None declared., F. Wijk: None declared.

Authors’ Affiliations

(1)
Pediatric Immunology, Wilhelmina Childrens'Hospital, University Medical Center Utrecht
(2)
Pediatric Immunology, University Medical Center
(3)
Pediatric Immunology, Wilhelmina Childrens Hospital, University Medical Center Utrecht

Copyright

© Vastert et al.; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement